amiodaron
use
sinc
antiarrhythm
drug
give
rise
varieti
cardiac
extracardiac
advers
sideeffect
among
pulmonari
toxic
consid
frequent
seriou
extracardiac
sideeffect
sinc
may
occur
variou
atyp
form
often
limit
drug
clinic
use
encount
white
male
patient
suspect
amiodaron
pneumon
character
multipl
lung
nodul
associ
pleural
pericardi
effus
peripher
neuropathi
differenti
diagnosi
pulmonari
infecti
diseas
may
extrem
difficult
attend
physician
therefor
bear
mind
possibl
amiodaron
pneumon
whenev
drug
given
age
clin
exp
re
amiodaron
pneumon
first
describ
earli
incid
amiodaron
lung
toxic
rang
patient
receiv
drug
estim
mortal
rate
case
mortal
hospit
subject
amiodaron
pneumon
risk
pulmonari
toxic
increas
advanc
age
higher
daili
dosag
restrict
lung
diseas
reduct
lung
diffus
capac
carbon
monoxid
pulmonari
function
test
blood
level
either
amiodaron
primari
metabolit
desethylamiodaron
predict
test
amiodaron
pulmonari
toxic
specif
clinic
radiograph
laboratori
find
relat
amiodaron
lung
toxic
radiolog
chang
rang
pure
alveolar
pattern
nearli
pure
interstiti
one
combin
two
common
present
singl
multipl
subpleur
mass
pulmonari
nodul
less
frequent
male
patient
admit
hospit
suspect
communityacquir
pneumonia
pulmonari
tuberculosi
treat
empir
antibiot
therapi
final
diagnos
amiodaron
pneumon
follow
neurolog
symptom
report
remind
clinician
bear
mind
drugrel
pneumon
neuropathi
differenti
diagnosi
infecti
diseas
white
male
present
fivemonth
histori
recurr
chest
pain
treat
antiinflammatori
therapi
one
month
hospit
develop
increas
chest
pain
weak
nighttim
intermitt
fever
chest
radiograph
chest
comput
tomographi
ct
show
multipl
irregular
consolid
mass
left
lung
associ
monolater
amiodaron
hydrochlorid
iodin
benzofuran
deriv
antiarrhythm
vasodilatatori
properti
first
introduc
europ
treat
angina
pectori
lifethreaten
ventricular
arrhythmia
atrial
fibril
howev
sever
advers
sideeffect
describ
amiodaron
therapi
first
report
includ
corneal
microdeposit
liver
toxic
thyroid
dysfunct
gastrointestin
disturb
bone
marrow
toxic
coagulopathi
cutan
reaction
peripher
neuropathi
pulmonari
diseas
recent
metaanalysi
random
control
trial
involv
patient
examin
use
amiodaron
vs
placebo
prevent
sudden
cardiac
death
show
amiodaron
therapi
associ
twoand
fivefold
increas
risk
pulmonari
thyroid
toxic
pleural
effus
pericardi
effus
mediastin
lymphadenopathi
fig
clinic
radiolog
find
indic
communityacquir
pneumonia
patient
treat
empir
antibiot
therapi
ceftriaxon
claritromycin
clinic
improv
one
month
later
admit
hospit
owe
persist
chest
pain
fever
patient
nonsmok
histori
recurr
atrial
fibril
highfrequ
ventricular
respons
treat
atrial
ablat
year
cardiovert
year
respect
hospit
amiodaron
therapi
month
mg
three
time
week
physic
examin
patient
afebril
eupnoic
blood
oxygen
satur
arteri
blood
pressur
mmhg
previou
week
daili
temperatur
rose
chest
pain
local
base
right
lung
worsen
respiratori
movement
chest
examin
decreas
vesicular
murmur
diffus
crackl
right
hemithorax
especi
base
heart
normal
laboratori
find
includ
increas
leukocyt
count
neutrophil
slight
anemia
hemoglobin
gdl
elev
creactiv
protein
mgdl
electrocardiogram
show
abnorm
differenti
diagnosi
broad
includ
infecti
noninfecti
pulmonari
diseas
bronchoscopi
show
normal
airway
without
endobronchi
lesion
cytolog
microbiolog
examin
bronchoalveolar
lavag
bal
neg
malign
cell
pathogen
microorgan
show
inflammatori
pattern
increas
number
granulocyt
lymphocyt
macrophag
bronchial
epithelium
cylindr
cell
particular
macrophag
contain
neither
vacuol
inclus
bodi
clinic
improv
observ
second
regimen
empir
antibiot
treatment
meropenem
ciprofloxacin
pleural
drainag
show
lemonyellow
liquid
test
neg
cytolog
microbiolog
examin
time
blood
sputum
cultur
also
neg
serum
tumor
marker
antinuclear
antimitochondri
antideoxyribonucl
acid
dna
c
antineutrophil
cytoplasm
anca
antilkm
antibodi
neg
lymphocyt
popul
studi
peripher
blood
cell
count
show
normal
count
increas
lymphocyt
count
human
immunodefici
viru
hiv
antibodi
test
neg
serum
antibodi
igm
antimycoplasma
pneumonia
chlamydia
pneumonia
chlamydia
psittaci
legionella
pneumophila
coxiella
burnetii
rickettsia
conori
nonreact
purifi
protein
deriv
ppd
test
show
posit
reaction
cutan
infiltr
hour
quantiferontb
test
neg
sinc
caus
infecti
etiolog
pulmonari
syndrom
found
system
corticosteroid
therapi
start
intraven
methylprednisolon
mg
daili
day
reduc
mg
daili
day
mg
daili
day
two
week
steroid
therapi
chest
pain
fever
disappear
chest
radiograph
confirm
almost
complet
resolut
lung
nodul
pleural
effus
patient
discharg
one
week
discontinu
flogisticreact
pattern
pulmonari
uptak
neg
steroid
therapi
ye
outcom
improv
n
steroid
therapi
chest
pain
fever
return
associ
perior
anesthesia
admit
day
hospit
pulmonari
scintigraph
studi
show
area
increas
uptak
lung
advers
reaction
amiodaron
consid
drug
discontinu
antiarrhythm
therapi
chang
introduc
flecainid
mg
daili
possibl
amiodaronerel
toxic
effect
abnorm
level
thyroid
hormon
corneal
microdeposit
found
discontinu
amiodaron
patient
report
rapid
complet
regress
fever
chest
pain
perior
anesthesia
followup
chest
ct
scan
week
later
show
resolut
pleuropericardi
effus
lung
nodul
signific
reduct
thorac
lymphadenopathi
patient
clinic
data
list
tabl
amiodaron
larg
use
treatment
supraventricular
ventricular
arrhythmia
nonischem
cardiomyopathi
sever
cardiac
extracardiac
sideeffect
may
occur
amiodaron
treatment
usual
relat
total
amount
drug
administ
extracardiac
amiodaron
toxic
may
involv
lung
liver
skin
nerv
organ
druginduc
abnorm
cell
tissu
aris
due
variou
patholog
mechan
induct
phospholipidosi
immunemedi
hypersensit
freerad
toxic
tissu
deposit
antiarrhythm
drug
major
sourc
side
effect
skin
decolor
experiment
data
show
vacuolar
sequestr
amiodaron
occur
concentr
close
therapeut
level
mediat
vatpas
evolv
toward
persist
macroautophagi
phospholipidosi
cytopatholog
cell
typespecif
tissu
macrophag
appear
particularli
suscept
amiodaron
interfer
endocyt
pathway
inhibit
proteolysi
caus
format
vacuol
uptak
intracellular
distribut
drug
function
consequ
amiodaron
accumul
remain
unclear
still
today
recent
vitro
studi
demonstr
amiodaron
associ
differ
cell
membran
accumul
acid
organel
inhibit
spread
coronaviru
respons
sever
acut
respiratori
syndrom
sar
postendosom
level
pneumon
seriou
advers
effect
one
lead
reason
stop
drug
may
develop
time
cours
treatment
report
case
mostli
observ
first
month
therapi
highdos
regim
therapi
mg
daili
relat
higher
incid
toxic
effect
predispos
factor
associ
pulmonari
toxic
includ
older
age
preexist
pulmonari
disord
mostli
caus
cigarett
smoke
neurolog
toxic
associ
amiodaron
treatment
uncommon
includ
tremor
gait
ataxia
peripher
neuropathi
cognit
impair
retrospect
analysi
cardiac
patient
treat
amiodaron
mayo
clinic
show
cumul
incid
probabl
druginduc
neurotox
effect
primari
risk
factor
reaction
durat
treatment
age
drug
dose
gender
indic
therapi
describ
old
nonsmok
patient
histori
atrial
fibril
develop
fever
thorac
pain
treat
lowdos
amiodaron
chest
ct
scan
show
multipl
lung
nodul
pleuropericardi
effus
thorac
lymphadenopathi
diseas
initi
consid
communityacquir
pneumonia
copres
pulmonari
mass
monolater
pleural
effus
enlarg
mediastin
lymphonod
failur
empir
antibiot
therapi
lead
us
consid
pulmonari
tuberculosi
microbiolog
search
neg
mycobacteria
quantiferontb
test
neg
amiodaron
toxic
consid
second
observ
patient
present
recurr
previou
thorac
symptom
steroid
discontinu
new
symptom
perior
anesthesia
amiodaron
toxic
may
also
observ
neuromuscular
system
character
polyradiculoneuropathi
anesthesia
paresthesia
possibl
aspecif
symptom
patient
present
probabl
peripher
nerv
involv
due
amiodaron
toxic
anesthet
sensat
perior
area
resolv
discontinu
drug
symptom
radiolog
find
clinic
symptom
amiodaroneinduc
pulmonari
toxic
aspecif
patient
develop
common
symptom
fever
chest
pain
late
peripher
nerv
involv
led
us
consid
toxic
noninfecti
caus
syndrom
rapid
disappear
toxic
effect
amiodaron
discontinu
certainli
remark
previou
extend
accumul
drug
tissu
unfortun
consensu
exist
regard
prevent
earli
detect
amiodaroneinduc
lung
toxic
accord
chang
et
al
diagnosi
base
clinic
laboratori
radiolog
criteria
includ
worsen
dyspnea
chest
radiograph
diffus
pulmonari
infiltr
pulmonari
function
declin
rule
congest
heart
failur
bronchoalveolar
fluid
phospholipidosi
lymphocytosi
patholog
find
regress
abnorm
amiodaron
withdraw
without
steroid
therapi
bronchoalveolar
fluid
usual
character
foami
cytoplasm
alveolar
macrophag
lymphocythosi
patient
fluid
show
bronchial
epithelium
cylindr
cell
histiocyt
granulocyt
sheet
lymphocyt
sheet
unfortun
lymphocyt
subpopul
studi
done
bal
lymphoamiodaroneinduc
toxic
cytosi
observ
peripher
blood
cell
count
pulmonari
scintigraphi
consid
earli
sensit
indic
amiodaron
pneumon
rare
use
high
cost
difficulti
interpret
lung
uptak
certainli
use
sensit
test
differenti
diagnosi
sarcoidosi
patient
lung
uptak
shown
probabl
owe
recent
discontinu
steroid
therapi
report
remind
clinician
recogn
treat
amiodaron
pneumon
earli
possibl
sinc
potenti
lifethreaten
lung
diseas
atyp
present
may
lead
erron
interpret
attend
physician
therefor
bear
mind
possibl
druginduc
lung
peripher
nerv
toxic
even
patient
receiv
lowdos
amiodaron
treatment
